Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma

Background: Recent studies have demonstrated benefits from adjuvant tyrosine-kinase inhibitors (TKIs) compared with chemotherapy in non-small cell lung cancer. We launched a multi-center retrospective study to evaluate the efficacy and toxicity of adjuvant TKIs with or without chemotherapy in epider...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qiwen, Ma, Li, Qiu, Bo, Wen, Yuzhi, Liang, Wenhua, Hu, Wanming, Chen, Naibin, Zhang, Tian, Xu, Shuangbing, Chen, Lingjuan, Guo, Minzhang, Zhao, Yi, Liu, Songran, Guo, Jinyu, Wang, Junye, Wang, Siyu, Wang, Xin, Pang, Qingsong, Long, Hao, Liu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167779/
https://www.ncbi.nlm.nih.gov/pubmed/33916930
http://dx.doi.org/10.3390/curroncol28020135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167779/
https://www.ncbi.nlm.nih.gov/pubmed/33916930
http://dx.doi.org/10.3390/curroncol28020135

Ejemplares similares